

the **ADBL** report

Issue #92, July 2016

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

EXPERT COMMITTEE MEMBERS:

Scott Klarenbach, MD, MSc (Health Econ), FRCPC (Chair)
Saibal Nandy, MBBS, MRCPsych, FRCPC (Vice-Chair)
Caitlin A. Clarke, BScPharm, PharmD
Glen J. Pearson, BScPhm, PharmD, FCSHP
Cheryl A. Sadowski, BSc (Pharm), PharmD, FCSHP
Jeremy Slobodan, BSP

ALBERTA HEALTH LIAISONS:

Michele Evans, BSP, MHSc (Health Admin)
Andrea Nagle, BSc (Pharm), LLB

ADMINISTRATIVE AND SCIENTIFIC SUPPORT:

Amanda Chung, BSc (Pharm)
Sherry Dieleman, BSc (Pharm), MSc
Connie Lussier, BSP, MA
Carlyn Volume-Smith, BSc (Pharm), MSc, PhD
Darcia Wasarab-Rolland, BSc (Pharm)

In this issue:

- *Brief Summary of Drug Review Activities*
- *Highlights of:*
 - ❖ *Products Originally Reviewed via the CDR*
 - ❖ *Interchangeable Drug Products added*
- *Special Authorization Criteria Changes*

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on May 16 & 17, 2016. The Committee reviewed Manufacturer submissions for forty-two (42) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of seventy-four (74) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, twenty-three (23) Drug Products underwent Expedited Review for listing on the *ADBL* effective June 1, 2016, and thirty (30) Drug Products underwent Expedited Review for listing on the *ADBL* effective July 1, 2016.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at

<https://www.ab.bluecross.ca/dbl/publications.html>

Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Products were reviewed by CDR and the Expert Committee and added to the *ADBL* via Step Therapy/Special Authorization (SA) effective June 1, 2016:

- **JARDIANCE*** (empagliflozin) (BOE) **10 mg & 25 mg tablets**

In keeping with recommendations from the CDR, the following Drug Products have NOT been added to the *ADBL*:

- **JINARC** (tolvaptan/tolvaptan) (OTS) **45 mg/15 mg, 60 mg/30 mg & 90 mg/30 mg combination packs**

A complete list of changes, as well as the full *ADBL* may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

*Please refer to the current *ADBL* for explanations of coverage, including a listing of coverage criteria (where applicable).*

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Expedited Entry IC Drug Products to the *ADBL* has resulted in the creation of New IC Groupings, effective July 1, 2016:

- **DULOXETINE** (duloxetine hydrochloride) (APX, AUR, JPC, MAR, MPI, PMS, RAN, SDZ, SIV, and TEV) **30 mg & 60 mg delayed-release capsules**
- **LUPIN-ESTRADIOL** (estradiol-17 β) (LPC) **0.5 mg, 1 mg & 2 mg tablets**

Special Authorization Criteria Changes

The Special Authorization criteria for coverage for the following Drug Product has been revised effective June 1, 2016:

- **NEUPOGEN*** (filgrastim) (AMG) **0.3 mg/mL injection**

A complete list of changes, as well as the full ADBL may be accessed at <https://www.ab.bluecross.ca/dbl/publications.html>.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).